ReviewBreast cancer (Dove Medical Press)2025
The Landscape of Potential Targeted Treatments and Chemotherapy Efficacy Biomarkers for TNBC.
Review in Breast cancer (Dove Medical Press), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple negative breast cancer (TNBC) is characterized as an estrogen receptor (ER) negative, progesterone receptor (PR) negative, and human epidermal growth factor receptor (HER-2) negative disease with an enhanced systemic metastatic incidence, chemotherapeutic insensitivity, and drug resistance. The internal characteristics of TNBC are extraordinary complex and are accompanied by numerous gene mutations and constitutively activated signaling networks, which, in turn, augment TNBC malignancy. There is an urgency to uncover new and potent therapeutic targets for TNBC. Herein, we discussed the historical as well as newly discovered subtypes and properties of TNBC. We also presented a systematic outline of the aberrant gene expression and abnormal activated signaling networks in TNBC. Subsequently, we summarized the corresponding targeted therapeutic drugs, and reviewed the current targeted TNBC therapies launched in clinical trials, thereby providing a direction for future TNBC therapy. We also provided a detailed list of coding genes involved in chemo-sensitive and chemo-resistance of TNBC, which can potentially serve as indicators of chemotherapeutic efficacy. Finally, we discussed the novel and future potential treatments of TNBC. This review highlighted the new era of TNBC treatment in the coming years and provided the gene expression profile of TNBC patients who may benefit from chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.